Development of a single vector system that enhances Trans-splicing of SMN2 transcripts

PLoS ONE

Volumn 3, Issue 10, 2008, Pages

  Coady, Tristan H ^a   Baughan, Travis D ^b   Shababi, Monir ^a   Passini, Marco A ^c   Lorson, Christian L ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

^c GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY RNA; RNA; SURVIVAL MOTOR NEURON PROTEIN; SURVIVAL MOTOR NEURON PROTEIN 2; TRANSFER RNA; UNCLASSIFIED DRUG; MESSENGER RNA;

ANIMAL EXPERIMENT; ANTISENSE VECTOR; ARTICLE; CONTROLLED STUDY; FIBROBLAST; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; RNA SPLICING; RNA VECTOR; SPLICEOSOME; TRANS SPLICING; ANIMAL; ANIMAL MODEL; CELL CULTURE; CELL LINE; CENTRAL NERVOUS SYSTEM; GENETICS; PATHOLOGY; SPINAL MUSCULAR ATROPHY;

MUS;

ANIMALS; CELL LINE; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM; FIBROBLASTS; HUMANS; MICE; MODELS, ANIMAL; MUSCULAR ATROPHY, SPINAL; RNA, ANTISENSE; RNA, MESSENGER; SURVIVAL OF MOTOR NEURON 2 PROTEIN; TRANS-SPLICING; TRANSFECTION;

EID: 55649102490     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003468     Document Type: Article

References (27)

1. Garcia-Blanco MA (2003) Messenger RNA reprogramming by spliceosome-mediated RNA trans-splicing. J Clin Invest 112:474-480.
2. Garcia-Blanco MA, Baraniak AP, Lasda EL (2004) Alternative splicing in disease and therapy. Nat Biotechnol 22:535-546.
3. Hengge UR (2008) SMaRT technology enables gene expression repair in skin gene therapy. J Invest Dermatol 128:499-500.
4. Rodriguez-Martin T, Garcia-Blanco MA, Mansfield SG, Grover AC, Hutton M, et al. (2005) Reprogramming of tau alternative splicing by spliceosome-mediated RNA trans-splicing: implications for tauopathies. Proc Natl Acad Sci U S A 102: 15659-5664.
5. Wally V, Klausegger A, Koller U, Lochmuller H, Krause S, et al. (2008) 5′ trans-splicing repair of the PLEC1 gene. J Invest Dermatol 128:568-574.
6. Zayed H, Xia L, Yerich A, Yant SR, Kay MA, et al. (2007) Correction of DNA protein kinase deficiency by spliceosome-mediated RNA trans-splicing and sleeping beauty transposon delivery. Mol Ther 15:1273-1279.
7. Wood M, Yin H, McClorey G (2007) Modulating the expression of disease genes with RNA-based therapy. PLoS Genet 3:e109.
8. Crawford TO, Pardo CA (1996) The neurobiology of childhood spinal muscular atrophy. Neurobiol Dis 3:97-110.
9. Oskoui M, Levy G, Garland CJ, Gray JM, O'Hagen J, et al. (2007) The changing natural history of spinal muscular atrophy type 1. Neurology 69:1931-1936.
10. Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, et al. (1995) Identification and characterization of a spinal muscular atrophy- determining gene. Cell 80:155-165.
11. Cartegni L, Krainer AR (2002) Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet 30:377-384.
12. Lorson CL, Hahnen E, Androphy EJ, Wirth B (1999) A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A 96:6307-6311.
13. Sumner CJ (2006) Therapeutics development for spinal muscular atrophy. NeuroRx 3:235-245.
14. Baughan T, Shababi M, Coady TH, Dickson AM, Tullis GE, et al. (2006) Stimulating full-length SMN2 expression by delivering bifunctional RNAs via a viral vector. Mol Ther 14:54-62.
15. Coady TH, Shababi M, Tullis GE, Lorson CL (2007) Restoration of SMN function: delivery of a trans-splicing RNA re-directs SMN2 pre-mRNA splicing. Mol Ther 15:1471-1478.
16. DiMatteo D, Callahan S, Kmiec EB (2008) Genetic conversion of an SMN2 gene to SMN1: a novel approach to the treatment of spinal muscular atrophy. Exp Cell Res 314:878-886.
17. Hua Y, Vickers TA, Baker BF, Bennett CF, Krainer AR (2007) Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon. PLoS Biol 5:e73.
18. Hua Y, Vickers TA, Okunola HL, Bennett CF, Krainer AR (2008) Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice. Am J Hum Genet 82:834-848.
19. Madocsai C, Lim SR, Geib T, Lam BJ, Hertel KJ (2005) Correction of SMN2 Pre-mRNA splicing by antisense U7 small nuclear RNAs. Mol Ther 12: 1013-1022.
20. Marquis J, Meyer K, Angehrn L, Kampfer SS, Rothen-Rutishauser B, et al. (2007) Spinal Muscular Atrophy: SMN2 Pre-mRNA Splicing Corrected by a U7 snRNA Derivative Carrying a Splicing Enhancer Sequence. Mol Ther.
21. de la Mata M, Alonso CR, Kadener S, Fededa JP, Blaustein M, et al. (2003) A slow RNA polymerase II affects alternative splicing in vivo. Mol Cell 12: 525-532.
22. Pellizzoni L (2007) Chaperoning ribonucleoprotein biogenesis in health and disease. EMBO Rep 8:340-345.
23. Gabanella F, Butchbach ME, Saieva L, Carissimi C, Burghes AH, et al. (2007) Ribonucleoprotein Assembly Defects Correlate with Spinal Muscular Atrophy Severity and Preferentially Affect a Subset of Spliceosomal snRNPs. PLoS ONE 2:e921.
24. Le TT, Pham LT, Butchbach ME, Zhang HL, Monani UR, et al. (2005) SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet 14:845-857.
25. Wolstencroft EC, Mattis V, Bajer AA, Young PJ, Lorson CL (2005) A nonsequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels. Hum Mol Genet 14: 1199-1210.
26. Shpargel KB, Matera AG (2005) Gemin proteins are required for efficient assembly of Sm-class ribonucleoproteins. Proc Natl Acad Sci U S A 102: 17372-17377.
27. Butchbach ME, Edwards JD, Burghes AH (2007) Abnormal motor phenotype in the SMNDelta7 mouse model of spinal muscular atrophy. Neurobiol Dis.